Johannes Reynisson j.reynisson@keele.ac.uk
Novel Tdp1 Inhibitors Based on Adamantane Connected with Monoterpene Moieties via Heterocyclic Fragments.
Reynisson
Authors
Abstract
Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is a promising target for anticancer therapy due to its ability to counter the effects topoisomerase 1 (Top1) poison, such as topotecan, thus, decreasing their efficacy. Compounds containing adamantane and monoterpenoid residues connected via 1,2,4-triazole or 1,3,4-thiadiazole linkers were synthesized and tested against Tdp1. All the derivatives exhibited inhibition at low micromolar or nanomolar concentrations with the most potent inhibitors having IC50 values in the 0.35-0.57 µM range. The cytotoxicity was determined in the HeLa, HCT-116 and SW837 cancer cell lines; moderate CC50 (µM) values were seen from the mid-teens to no effect at 100 µM. Furthermore, citral derivative 20c, a-pinene-derived compounds 20f, 20g and 25c, and the citronellic acid derivative 25b were found to have a sensitizing effect in conjunction with topotecan in the HeLa cervical cancer and colon adenocarcinoma HCT-116 cell lines. The ligands are predicted to bind in the catalytic pocket of Tdp1 and have favorable physicochemical properties for further development as a potential adjunct therapy with Top1 poisons.
Citation
Reynisson. (2021). Novel Tdp1 Inhibitors Based on Adamantane Connected with Monoterpene Moieties via Heterocyclic Fragments. Molecules, 1-23. https://doi.org/10.3390/molecules26113128
Acceptance Date | May 21, 2021 |
---|---|
Publication Date | May 24, 2021 |
Journal | Molecules |
Publisher | MDPI |
Pages | 1-23 |
DOI | https://doi.org/10.3390/molecules26113128 |
Keywords | topoisomerase 1; monoterpenoid; cancer; DNA repair enzyme; SAR; molecular modeling; chemical space |
Publisher URL | https://www.mdpi.com/1420-3049/26/11/3128 |
Files
molecules-26-03128-v4.pdf
(6.1 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
Accessing active fragments for drug discovery utilising nitroreductase biocatalysis.
(2024)
Journal Article
Phosphatidylcholine-Specific Phospholipase C as a Promising Drug Target
(2023)
Journal Article